Evidence map›Paper›PMID 40593194›Full record

ArticlePituitary2025

Endoscopic endonasal transcavernous surgery for a contemporary series of 59 prolactinomas.

Taishi Nakase, Vladimir A Ljubimov, Julia J Chang, Hannes Vogel, Vera Vigo, Laurence Katznelson, Juan Carlos Fernandez-Miranda

Abstract read
PubMed Publisher
In one paragraph

Article in Pituitary, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Taishi NakaseDepartment of Neurosurgery, Stanford University, Stanford, CA, USA.
Vladimir A LjubimovDepartment of Neurosurgery, Stanford University, Stanford, CA, USA.
Julia J ChangDepartment of Neurosurgery, Stanford University, Stanford, CA, USA.
Hannes VogelDivision of Neuropathology, Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
Vera VigoDepartment of Neurosurgery, Stanford University, Stanford, CA, USA.
Laurence KatznelsonDivision of Endocrinology, Gerontology, and Metabolism, Department of Medicine, Stanford University, Stanford, CA, USA.
Juan Carlos Fernandez-MirandaDepartment of Neurosurgery, Stanford University, Stanford, CA, USA. drjfm@stanford.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo assess surgical outcomes in patients with prolactinomas treated surgically with contemporary endoscopic endonasal techniques within the context of recent advances in transcavernous approaches and shifts towards surgery as a primary treatment option alongside dopamine agonists.

methodsSurgical outcomes were retrospectively analyzed for 59 consecutive patients with prolactinomas who underwent endoscopic endonasal surgery between October 2018 and December 2024.

resultsThe cohort included 42 (71%) patients with macroprolactinomas and 32 (54%) patients with cavernous sinus (CS) invasion, including 14 (24%) with isolated medial wall invasion and 18 (31%) with CS compartment invasion. Median follow-up was 19 months (interquartile range = 10-38). Overall, 82% of patients demonstrated normoprolactinemia within three days of surgery and 80% (74% macroprolactinoma, 94% microprolactinoma) achieved biochemical remission at last follow-up. Adjuvant dopamine agonist treatment and/or radiation increased the long-term remission rate to 86% overall and to 83% for macroprolactinomas. Among patients for whom total resection (vs. debulking) was the primary surgical goal, long-term biochemical remission was achieved in 84% of patients (88% with adjuvant therapy). One operative complication with no neurological sequelae occurred in a patient with a giant invasive adenoma. Permanent arginine vasopressin deficiency was observed in three patients and transient diplopia was observed in four patients.

conclusionThe addition of endoscopic transcavernous approaches for prolactinoma resection can be safe and effective in selected patients after multidisciplinary evaluation when performed by an experienced neurosurgical team, providing further support for the wider adoption of surgery in the management of prolactinomas.

Indexed as

Pituitary NeoplasmsProlactinomaAdultCavernous SinusDopamine AgonistsFemaleHumansMaleMiddle AgedRetrospective StudiesTreatment OutcomeDopamine AgonistsEndoscopic endonasal surgeryPituitary adenomaProlactinomaRemissionTranscavernous

Identifiers

PMID40593194

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.